The use of vascular endothelial growth factor (VEGF) inhibitors has revolutionised the treatment of neovascular age-related macular degeneration (nAMD) since the pivotal Phase III studies demonstrated their efficacy more than 10 years ago. The Fight Retinal Blindness! project was developed to track the treatment outcomes of patients with nAMD in real-world practice. Data from this registry have been used to answer several clinically relevant questions related to the treatment of nAMD including the effect of under-treatment, the comparative effectiveness of different anti-vascular endothelial growth factor agents, long-term treatment outcomes, identifying optimal treatment regimens and the rate and outcomes of rare adverse events. Observational studies are a valuable complement to the shortcomings of clinical trials and a combination of data from real-world settings and clinical trials are necessary to provide evidence on how to achieve the best outcomes for individual patients with nAMD.

中文翻译：

---

新生血管性年龄相关性黄斑变性：现实世界抗击视网膜失明研究结果综述！注册表


自从十多年前关键的 III 期研究证明了血管内皮生长因子 (VEGF) 抑制剂的疗效以来，血管内皮生长因子 (VEGF) 抑制剂的使用彻底改变了新生血管性年龄相关性黄斑变性 (nAMD) 的治疗方法。对抗视网膜失明！该项目旨在跟踪现实世界中 nAMD 患者的治疗结果。该登记数据已用于回答与 nAMD 治疗相关的几个临床相关问题，包括治疗不足的影响、不同抗血管内皮生长因子药物的比较疗效、长期治疗结果、确定最佳治疗方案以及罕见不良事件的发生率和结果。观察性研究是对临床试验缺点的宝贵补充，需要结合现实环境和临床试验的数据，为如何为 nAMD 个体患者实现最佳结果提供证据。